英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
niculum查看　niculum　在百度字典中的解释百度英翻中〔查看〕
niculum查看　niculum　在Google字典中的解释Google英翻中〔查看〕
niculum查看　niculum　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Bispecific T-Cell Engager for Relapsed Refractory Multiple Myeloma . . .
    Initiate treatment with LYNOZYFIC step-up dosing to reduce the risk of CRS Manage CRS, withhold LYNOZYFIC until CRS resolves, and modify the next dose or permanently discontinue based on severity
  • Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for . . .
    Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy
  • Pharmacists Application to Practice: Linvoseltamab-gcpt
    Linvoseltamab-gcpt (Lynozyfic) is a bispecific B-cell maturation antigen (BCMA)- direct CD3 T-cell engager 1 BCMA is expressed on plasmablasts and plasma cells 2 It has emerged as a useful drug target for the treatment of multiple myeloma
  • LYNOZYFIC™ (linvoseltamab-gcpt) is now approved!
    LYNOZYFIC is now approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody
  • Review - accessdata. fda. gov
    Regeneron did not provide a derivation or intended meaning for the proposed proprietary name, Lynozyfic, in their submission This proprietary name is comprised of a single word that contains the
  • Lynozyfic (linvoseltamab): A New Option for Patients With Relapsed or . . .
    Dr Hans Lee provides an overview of the recent approval of Lynozyfic (linvoseltamab) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least
  • epocrates Web
    FDA granted accelerated approval to Lynozyfic (linvoseltamab-gcpt), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who’ve received ≥ 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal ant
  • Regeneron - Lynozyfic - Pennsylvania Society of Oncology and Hematology
    Enrollment is the first step to accessing support for benefits investigation, prior authorizations, claims, and appeals For more information or support, please reach out to your Oncology Reimbursement Manager, call 1 844 RGN HEME (1 844 746 4363), Option 1, Monday–Friday,8 am–8 pm Eastern time, or visit LYNOZYFIChcp com This material is provided for informational purposes only, is subject to change, and should not be construed as legal or medical advice
  • From Relapse to Response: How T-Cell Engagers Are Changing the Multiple . . .
    Primary intervention is the application of dexamethasone, a potent steroid medication, to decrease inflammation and slow down the overactive immune system Currently, four TCE BsAbs have received FDA approval for the treatment of RRMM
  • LYNOZYFIC™ (linvoseltamab-gcpt) is now approved!
    For more information or support, please reach out to your Oncology Reimbursement Manager, call 1 844 RGN HEME (1 844 746 4363), Option 1, Monday–Friday, 8 am–8 pm Eastern time, or visit LYNOZYFIChcp com





中文字典-英文字典  2005-2009